pharmaphorum16h
Novo puts $285m into monthly GLP-1 based on Ascendis tech
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
BioPharma Dive1d
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Quartz on MSN1d
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...
Benzinga.com13h
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis ...
FierceBiotech1d
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...